Description
Technical Information & Resources
Frequently Asked Questions
Why use the dihydrochloride salt form of LDN-193189?
TrailBio® LDN-193189 provides improved aqueous solubility compared to the free-base version and can therefore be reconstituted in sterile water or aqueous buffer at ≥25 mg/ml. This minimizes the need for the addition of DMSO to culture media, protecting cells from cytotoxicity.
How specific is LDN-193189?
TrailBio® LDN-193189 is a potent BMP type I receptor inhibitor commonly used to inhibit ALK2/ALK3-mediated signaling. Activity against other BMP type I receptors, including ALK1 and ALK6, has also been reported, and selectivity is concentration- and assay-dependent; users should titrate the compound for their specific cell type and workflow.
Supporting Publications
Yu et al. (2008), Nature Chemical Biology
- Foundational publication identifying dorsomorphin as a selective small-molecule inhibitor of BMP type I receptor signaling, including inhibition of ALK2, ALK3, ALK6, and downstream SMAD1/5/8 phosphorylation.
Cuny et al. (2008), Bioorg Med Chem Lett
- Cuny et al. used structure–activity relationship optimization of dorsomorphin-derived BMP inhibitors to develop more potent analogs, including LDN‑193189.
Yu et al. (2008), Nature Medicine
- Yu et al. demonstrated that pharmacologic inhibition of BMP type I receptors with LDN‑193189 suppresses SMAD1/5/8 signaling and reduces heterotopic ossification.
